Gapping up
In reaction to strong earnings/guidance:
- MBUU +10.5%, ELF +10.2%, SONO +9.1%, TWTR +8.3%, USX +7.5%, RAMP +6.3%, QNST +6.2%, CAH +5.4%, GLUU +4.7%, ZNGA +4.6%, ACLS +4.6%, IRBT +4.4%, HAIN +4.4%, REGN +4.3%, CSGS +4%, SNY +3.6%, NGL +3.5%, SPGI +3.5%, TTMI +3.3%, ENSG +3.3%, FOXA +3.2%, ECHO +3.2%, BMY +2.9%, FCAU +2.8%, SAVE +2.7%, TGI +2.7%, ING +2.4%, COHR +2.3%, MC +2.3%, LNC +2.2%, FLO +2.2%, RDN +2.1%, TPR +2.1%, OIIM +2%, LL +1.8%, NOK +1.7%, CTSH +1.6%, CUZ +1.5%, DNKN +1.3%, AVXL +1.3%, NRZ +1.2%, ICE +1.2%
Other news:
- UIS +15.8% (to sell the company's U.S. Federal business to Science Applications International (SAIC) for $1.2 bln, sees FY 19 revs growth towards upper end of guidance range)
- AQST +10.7% (announces FDA confirmed 505(b)(2) pathway for AQST-108 following face-to-face pre-IND meeting)
- LDOS +8.3% (awarded $7.73 bln US Navy contract)
- ARWR +7.5% (reports interim clinical results from Phase 1/2a studies of ARO-APOC3 and ARO-ANG3; also reports earnings)
- MLCO +3.2% (has taken the decision to reassess all non-core investments to be made in 2020)
- BCEL +2.4% (strategic collaboration with Merck)
- JJSF +1.7% (acquires assets of BAMA ICEE)
- VLRS +1.3% (reports January passenger growth increased 17% yr/yr)
Analyst comments:
- MU +2.3% (upgraded to Strong Buy from Mkt Perform at Raymond James)
- VMW +1.6% (upgraded to Outperform from Mkt Perform at Bernstein)
- PAA +1.5% (upgraded to Buy from Neutral at Goldman)
- GD +1.3% (upgraded to Overweight from Neutral at JP Morgan)